<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01068353</url>
  </required_header>
  <id_info>
    <org_study_id>STEADI-09</org_study_id>
    <secondary_id>2009-013400-31</secondary_id>
    <nct_id>NCT01068353</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Etanercept in Alzheimer's Disease</brief_title>
  <acronym>STEADI-09</acronym>
  <official_title>A Phase 2, Double-blind, Placebo-controlled Study of the Safety and Tolerability of Etanercept in Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southampton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hampshire Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southampton</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the study is to determine the safety and tolerability of etanercept in
      subjects with Alzheimer's Disease. The effects of etanercept on cognitive, behavioural,
      functional and immunological outcomes will be examined as secondary aims.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events and serious adverse events (the study is a Phase II safety trial)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in change in Alzheimer's Disease Assessment Scale - Cognitive Section (ADAS-cog) total score between treated and placebo groups from baseline to end point at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in Neuropsychiatric Inventory (NPI) total score between treated and placebo groups from baseline to end point at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in Clinician's Global Impression of Change (CGIC) and Carer's Impression of Change (Carer-IC) total score between treated and placebo groups from baseline to end point at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in Mini-Mental State Examination (MMSE) total score between treated and placebo groups from baseline to end point at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in change in Sickness Behaviour Scale between treated and placebo groups from baseline to end point at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To establish whether a pro-inflammatory baseline cytokine profile predicts better response to treatment with etanercept</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To examine the effects of etanercept on inflammatory markers in the cerebrospinal fluid (CSF) of patients with Alzheimer's disease, and the relationship of these factors with clinical outcome</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>50 mg given as a once weekly subcutaneous injection</description>
    <arm_group_label>Etanercept</arm_group_label>
    <other_name>Enbrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injection given once weekly</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged &gt; 54 years

          -  Have a minimum of 7 years of education

          -  Be able to hear, read, write and perform study neuropsychological tests in English

          -  Have adequate visual and auditory acuity to allow neuropsychological testing based on
             the research clinician's judgement

          -  Fulfil Diagnostic &amp; Statistical Manual (DSM-IV-TR)criteria for diagnosis of dementia
             of the Alzheimer type

          -  Have a diagnosis of probable Alzheimer's Disease (National Institute of Neurological
             and Communicative Disorders and Stroke and the Alzheimer's Disease and Related
             Disorders Association (NINCDS-ADRDA) criteria)

          -  Mini Mental State Examination (MMSE) score &lt; 27 and &gt; 10 points.

          -  To be currently taking and have been taking a cholinesterase inhibitor for a minimum
             period of 3 months prior to the day of inclusion into the study or to have been not
             been taking a cholinesterase inhibitor for a minimum period of 3 months prior to the
             day of inclusion into the study

          -  Have an informant who spends at least 24 hours per week with the patient and may be a
             close friend or a neighbour, not necessarily a close relative, spouse, son or
             daughter. He/she should be the same throughout the study and should be present at all
             visits. If it becomes necessary, a change of informant can be made but this must be
             clearly documented.

        Exclusion Criteria:

          -  Inability or refusal to provide informed consent from patient or caregiver

          -  Absence of informant

          -  Unlikely to cooperate in the study, not able to attend scheduled examinations and
             visits, or not able to follow study instructions

          -  Participation in another study with administration of any investigational drug in the
             previous 3 months or already enrolled in another study

          -  Parkinson's Disease, Dementia with Lewy Bodies or clinically significant Parkinsonian
             symptoms

          -  Vascular disorder (modified Hachinski Ischaemic Scale score &gt; 4)

          -  Recent Transient Ischaemic Attack (TIA) - within the last 3 months

          -  Signs of major cerebrovascular disease on MRI or CT scan, if performed prior to entry
             into study (i.e. presence of infarction in greater than 25% of white matter, more than
             1 lacune within basal ganglia, more than 2 lacunes in white matter)

          -  Any other previous or ongoing chronic or recurrent disease of the central nervous
             system, including demyelinating disease or psychiatric diseases, that may have an
             impact on cognitive performance, left to the research clinician's judgement

          -  Any of the following laboratory abnormalities at the screening visit:

             i) Clinically significant Vitamin B12 levels less than the lower limit of normal ii)
             Clinically significant folate levels less than the lower limit of normal iii)
             Clinically significant thyroid-stimulating hormone (TSH) levels greater than the upper
             limit of normal and a clinically significant free thyroxine (FT4) level lower than the
             lower limit of normal

          -  Patients with previous or present history of severe or unstable medical conditions
             (e.g. hypertension, diabetes left to the research clinician's judgement)

          -  Current alcohol &gt;35 units per week for men, or &gt;28 units per week for women, or drug
             abuse at the discretion of the research clinician

          -  Surgical intervention planned during the study period.

          -  Treatment with immunosuppressive drugs and/or oral prednisone greater than 10mg/day
             within the past 90 days

          -  Treatment with Memantine within the past 3 months

          -  Vaccination or immunization with any live vaccine (eg: polio, rubella, yellow fever)
             or the pneumococcal vaccine within the past 30 days.

          -  Pregnancy or breast feeding.

          -  Severe hepatic, renal or cardiac disease.

          -  Previous use of a Tumour Necrosis Factor-alpha (TNFÎ±) agent.

          -  Known skin photosensitivity.

          -  Infection in past 4 weeks or active infection.

          -  Heart failure: New York Heart Association (NYHA) Grade 3-4.

          -  History of blood disorders or current WCC â¤ 3.5 x 109/l; platelet count â¤ 100x109/l ;
             Hb â¤ 10g/dl.

          -  Active or latent tuberculosis

          -  Rheumatoid arthritis; psoriasis; psoriatic arthritis or ankylosing spondylitis

          -  Septic arthritis in past 12 months

          -  Sepsis of prosthesis in past 12 months

          -  Chronic leg ulcers

          -  Indwelling urinary catheter

          -  Pulmonary fibrosis

          -  History of neoplasms / malignancies in past 5 years

          -  Pre-malignant conditions including Barrett's oesophagus; cervical dysplasia; large
             bowel polyps

          -  Any relevant acute or chronic abnormality detected during the physical and
             neurological examinations. Electrocardiogram (ECG) or laboratory tests likely to
             interfere with the study evaluations in the research clinician's judgement

          -  Previous exposure to amyloid vaccines, monoclonal antibodies or intravenous
             immunoglobulins meant to treat Alzheimer's disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Memory Assessment and Research Centre, Moorgreen Hospital</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO30 3JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2010</study_first_submitted>
  <study_first_submitted_qc>February 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2010</study_first_posted>
  <last_update_submitted>April 22, 2014</last_update_submitted>
  <last_update_submitted_qc>April 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Dementia</keyword>
  <keyword>TNF-alpha</keyword>
  <keyword>Etanercept</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

